Article
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
Arthritis and rheumatism - 15 Jan 2009
Albers H M, Wessels J A M, van der Straaten R J H M, Brinkman D M C, Suijlekom-Smit L W A, Kamphuis S S M, Girschick H J, Wouters C, Schilham M W, le Cessie S, Huizinga T W J, Ten Cate R, Guchelaar H J
Abstract excerpt
OBJECTIVE: Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug in juvenile idiopathic arthritis (JIA). Currently, individual response to MTX cannot be reliably predicted. Identification of clinical and genetic factors that influence the response to MTX could be helpful in realizing the optimal treatment for individual patients. METHODS: A cohort of 128 JIA patients treated with MTX...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
